Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 7Melanoma 7Lung Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Esophageal Neoplasms 4Uterine Cervical Neoplasms 3Rectal Neoplasms 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Pathologic Complete Response 2Pancreatic Neoplasms 2Neoplasm, Residual 2Hyperthermia 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Breast Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Radiation Pneumonitis 1

Interventions

Trastuzumab 303Paclitaxel 256Cyclophosphamide 251Docetaxel 238Capecitabine 175Letrozole 163Carboplatin 163Doxorubicin 145Fulvestrant 144Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 88Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 44Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Immunotherapy × Clear all
NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
119 enrolled
Breast

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT07254858 2025-11-28

CISN-L

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Not yet recruiting
302 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡